Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Magicbuvir Plus vs Harvoni in Healthy Volunteers
NCT03005210Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Nov 2016
- Primary completion
- Nov 2016
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Harvoni in hepatitis C virus infection (3 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration, Area under the concentration-time curve from time zero to the last measurable concentration and 1 more. Started Nov 2016; status: completed.
02
Drugs
Harvoni
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT03005210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005210.